- Home
- EB vs TSHA Comparison
EB vs TSHA Comparison
Compare EB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EB
- TSHA
- Stock Information
- Founded
- EB 2008
- TSHA 2019
- Country
- EB United States
- TSHA United States
- Employees
- EB N/A
- TSHA N/A
- Industry
- EB EDP Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EB Technology
- TSHA Health Care
- Exchange
- EB Nasdaq
- TSHA Nasdaq
- Market Cap
- EB 343.9M
- TSHA 403.7M
- IPO Year
- EB 2018
- TSHA 2020
- Fundamental
- Price
- EB $3.60
- TSHA $1.97
- Analyst Decision
- EB Buy
- TSHA Strong Buy
- Analyst Count
- EB 6
- TSHA 8
- Target Price
- EB $6.70
- TSHA $6.63
- AVG Volume (30 Days)
- EB 1.4M
- TSHA 5.4M
- Earning Date
- EB 11-07-2024
- TSHA 11-13-2024
- Dividend Yield
- EB N/A
- TSHA N/A
- EPS Growth
- EB N/A
- TSHA N/A
- EPS
- EB N/A
- TSHA N/A
- Revenue
- EB $336,368,000.00
- TSHA $9,915,000.00
- Revenue This Year
- EB $2.57
- TSHA N/A
- Revenue Next Year
- EB $4.65
- TSHA N/A
- P/E Ratio
- EB N/A
- TSHA N/A
- Revenue Growth
- EB 8.54
- TSHA N/A
- 52 Week Low
- EB $2.51
- TSHA $1.19
- 52 Week High
- EB $9.20
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- EB 48.67
- TSHA 41.45
- Support Level
- EB $3.50
- TSHA $1.97
- Resistance Level
- EB $3.79
- TSHA $2.72
- Average True Range (ATR)
- EB 0.21
- TSHA 0.23
- MACD
- EB -0.04
- TSHA -0.10
- Stochastic Oscillator
- EB 11.11
- TSHA 2.24
About EB Eventbrite Inc.
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. It is engaged in creating a platform to enable creators to solve many challenges associated with creating live experiences. The Company's platform integrates components needed to seamlessly plan, promote and produce live events. Its platform helps to plan, promote and produce live events, thereby allowing creators to reduce friction and costs, increase reach and drive ticket sales. Geographically, it generates maximum revenue from the United States.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.